Abstract. Quadruplet regimens (anti-CD38 monoclonal antibodies [mAbs] with proteasome inhibitor [PI] and immunomodulatory drugs [IMiDs]) are increasingly b
Research by Fred Hutch Cancer Center genetic epidemiologist Burcu Darst, PhD, and scientists from the Canary Prostate Active Surveillance Study (PASS), suggests that a patient’s…
Ruth Jessen Hickman, MD, is a freelance medical and science writer based in Bloomington, Indiana. Population: Roughly 1 in 200,000 people across ethnicities; may present…
Melissa B. Davis, PhD, on Thursday addressed the challenges of unraveling social versus biological drivers of racial disparities in cancer outcomes.
Overview for AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals
We present data on radiographic responses to ICI therapy in advanced melanoma patients with tumors harboring NF1 (Neurofibromatosis 1) mutations.
The PACIFIC-5 study has met its primary end point of improved PFS with consolidation durvalumab after CRT in select unresectable stage III NSCLC.
Results of major clinical trial may pave the way to health insurance coverage for treatment-resistant cases
As the number of recipients of chimeric antigen receptor (CAR) T-cell therapies has rapidly increased, sporadic reports of T-cell lymphomas arising de novo
Oncogene – Tissue factor promotes TREX1 protein stability to evade cGAS-STING innate immune response in pancreatic ductal adenocarcinoma
Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the potential use of GLP-1 or GLP agonist and incretin mimetics during…
